Crossmark

Using a qualitative sub-study to inform the design and delivery of randomised controlled trials on medicinal cannabis for symptom relief in patients with advanced cancer

Crossref DOI link: https://doi.org/10.1186/s13063-022-06691-1

Published Online: 2022-09-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Olson, Rebecca E. https://orcid.org/0000-0002-7721-8708
Smith, Alexandra

Huggett, Georgie

Good, Phillip

Dudley, Morgan

Hardy, Janet
Funding

Funding for this research was provided by:

National Health and Medical Research Council (APP1140160)

Mater Foundation (Mater Clinical Research Seeding Grant 2017)
License Information

Text and Data Mining valid from 2022-09-05

Version of Record valid from 2022-09-05
More Information

Article History

Received: 4 April 2022

Accepted: 24 August 2022

First Online: 5 September 2022

Declarations

:

: Ethical approval for this study was obtained from the Human Research Ethics Committees at the Mater Hospital (HREC/17/MHS/97) and St Vincent’s Hospital (HREC 17/27). All participants provided their written consent.

: Not applicable. All personal data is de-identified.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below